---
id: 149
title: Clostridioides difficile Infection
category: organisms
subcategory: anaerobic_bacteria
tags: [C-diff, CDI, vancomycin, fidaxomicin, fecal-transplant, pseudomembranous-colitis]
difficulty: medium
---

## Question

How is *C. difficile* infection severity classified and treated? Use the **"Non-Severe: PO Vanc/Fidaxo × 10d, Severe: PO Vanc × 10d, Fulminant: PO+PR Vanc + IV Metro"** framework.

## Answer

### ***Clostridioides difficile* Infection (CDI) Overview:**

**Transmission:** Fecal-oral, healthcare-associated (most common), community-acquired (increasing)

**Risk Factors:**
- **Antibiotic exposure** (especially fluoroquinolones, clindamycin, cephalosporins, carbapenems)
- **Age >65 years**
- **Hospitalization, long-term care**
- **PPI use** (controversial, modest association)
- **Immunosuppression**

### **Clinical Presentation:**

**Symptoms:**
- **Diarrhea** (≥3 unformed stools/24h)
- **Abdominal pain/cramping**
- **Fever, leukocytosis** (WBC often >15,000)
- **Pseudomembranous colitis** (severe cases)

**Diagnosis:**
- **NAAT (PCR)** OR **GDH + toxin EIA** (two-step algorithm)
- **Test only symptomatic patients** with ≥3 unformed stools/24h
- **DO NOT test for cure** (remain NAAT+ for weeks after treatment)

### **Severity Classification:**

| Severity | Criteria | Treatment |
|----------|----------|-----------|
| **Non-Severe** | WBC ≤15,000 AND Cr <1.5× baseline | **Fidaxomicin 200mg PO BID × 10d** (preferred)<br>OR **vancomycin 125mg PO QID × 10d** |
| **Severe** | WBC >15,000 OR Cr ≥1.5× baseline | **Vancomycin 125mg PO QID × 10d**<br>OR **fidaxomicin 200mg PO BID × 10d** |
| **Fulminant** | Hypotension, shock, ileus, megacolon, ICU admission | **Vancomycin 500mg PO/NG QID** + **metronidazole 500mg IV q8h**<br>If ileus: **vancomycin 500mg PR q6h** (retention enema) |

### **Treatment Details:**

**Initial Episode:**

**Non-Severe/Severe:**
- **Fidaxomicin 200mg PO BID × 10 days** (preferred, lower recurrence)
- **Vancomycin 125mg PO QID × 10 days** (alternative)
- **Avoid metronidazole** (inferior efficacy, reserved for fulminant + vanc)

**Fulminant:**
- **Vancomycin 500mg PO/NG QID** (high dose)
- **+ Metronidazole 500mg IV q8h**
- **If ileus/toxic megacolon:** Add **vancomycin 500mg PR q6h** (via rectal catheter, retention enema)
- **Surgery:** Total colectomy if peritonitis, perforation, refractory shock (mortality ~50%)

**Recurrent CDI:**

**First Recurrence:**
- **Fidaxomicin 200mg PO BID × 10 days** (preferred)
- OR **vancomycin 125mg PO QID × 10d, then taper/pulse**:
  - 125mg PO BID × 7d → 125mg PO daily × 7d → 125mg PO every 2-3 days × 2-8 weeks

**Second/Multiple Recurrences:**
- **Fidaxomicin 200mg PO BID × 10d** (preferred)
- OR **vancomycin taper/pulse** (above)
- OR **bezlotoxumab 10 mg/kg IV × 1** (monoclonal antibody against toxin B) + standard antibiotics
- OR **fecal microbiota transplantation (FMT)** - cure rate >90% for multiple recurrences

### **Fecal Microbiota Transplantation (FMT):**

**Indications:**
- **≥2 recurrences** after appropriate antibiotics
- **Cure rate:** >90%

**Administration:**
- **Colonoscopy** (most common)
- **Capsules** (FDA-approved products available)
- **NG tube** (less preferred)

**Screening:** Donor screened for enteric pathogens, bloodborne viruses, resistant organisms

## Key Points

### **DO NOT Use Metronidazole for Initial/Recurrent CDI:**
- **Inferior to vancomycin/fidaxomicin** (lower cure, higher recurrence)
- **Reserve for fulminant CDI** (+ vancomycin) due to systemic absorption

### **Why NOT Test for Cure:**
- **NAAT remains positive** for weeks after successful treatment (detects DNA, not active infection)
- **Only retest if symptoms recur**

### **Recurrence Risk:**
- **15-25% after first episode**
- **40-60% after second episode**
- **>60% after multiple recurrences**

### **Infection Control:**
- **Contact precautions** (gown, gloves)
- **Private room** preferred
- **Hand hygiene:** Soap and water (alcohol gel does NOT kill spores)
- **Environmental cleaning:** Bleach-based disinfectants (sporicidal)

### **Antibiotic Stewardship:**
- **Avoid high-risk antibiotics** if possible (fluoroquinolones, clindamycin, cephalosporins, carbapenems)
- **Shorten antibiotic duration** when appropriate
- **Most important prevention strategy**

### **Bezlotoxumab:**
- **Monoclonal antibody** against *C. difficile* toxin B
- **Reduces recurrence** by ~40% (does NOT treat active infection)
- **Give with antibiotics** in high-risk patients (age >65, recurrent CDI, immunosuppressed)

### **Clinical Pearls:**
- **Non-severe/severe:** Fidaxomicin or vancomycin 125mg QID × 10 days
- **Fulminant:** Vancomycin 500mg QID PO/NG + metronidazole IV (± PR vanc if ileus)
- **Recurrent:** Fidaxomicin > vancomycin taper/pulse > FMT (≥2 recurrences)
- **DO NOT test for cure** (NAAT stays positive)
- **Hand hygiene:** Soap and water (alcohol does NOT kill spores)
- **FMT cure rate >90%** for multiple recurrences

## Sources

- [IDSA/SHEA: *C. difficile* Infection Guidelines 2024]
- [ACG: *C. difficile* Infection Clinical Guidelines 2024]

## Media

N/A
